trial · primary record
NT-0796
Obesity
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 82 |
| Primary completion | 2026-08-21 |
| Primary endpoint | Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs. |
| Registry ID | NCT07220629 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:28.583Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07220629
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.